Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001897612-25-000217
Filing Date
2025-05-14
Accepted
2025-05-14 10:47:09
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 5911
  Complete submission text file 0001897612-25-000217.txt   7730
Mailing Address 90 PARK DRIVE MILTON PARK, ABINGDON OXFORDSHIRE X0 OX14 4RY
Business Address 90 PARK DRIVE MILTON PARK, ABINGDON OXFORDSHIRE X0 OX14 4RY 01235 5430281
Immunocore Holdings plc (Subject) CIK: 0001671927 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-92246 | Film No.: 25943493
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 1307 POINT STREET BALTIMORE MD 21231
Business Address 1307 POINT STREET BALTIMORE MD 21231 000-000-0000
T. Rowe Price Investment Management, Inc. (Filed by) CIK: 0001897612 (see all company filings)

EIN.: 854328500 | State of Incorp.: MD | Fiscal Year End: 1231
Type: SCHEDULE 13G/A